Currently approved chimeric antigen receptor (CAR) T-cell therapies are predominantly autologous, which presents issues in terms of manufacturing time and T-cell quality. Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents preliminary safety and efficacy data of PBCAR0191, an allogeneic CD19-directed CAR T-cell therapy, in patients with B-cell acute lymphoblastic leukemia (B-ALL). Increased dosages of fludarabine and cyclophosphamide for lymphodepletion resulted in more successful CAR T-cell expansion and deeper remission. A favorable safety profile was reported and a number of patients were subsequently eligible for allogeneic stem cell transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

свернуть